POLD3
ENSG00000077514
Target class
Enzyme
Chromosome
11
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- POLD3
- Gene name
- DNA polymerase delta 3, accessory subunit
- Gene symbol
- POLD3
- Protein name
- DNA polymerase delta subunit 3 (DNA polymerase delta subunit C) (DNA polymerase delta subunit p66) (DNA polymerase delta subunit p68)
- P66
- KIAA0039
- P68
- PPP1R128
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases|Protein phosphatase 1 regulatory subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 27.01
- Tissue specificity (Gini)
- 0.332
- Tissue specificity (tau)
- 0.712
- KEGG gene identifiers
- hsa:10714
- Protein interaction confidence
- 0.89115
- Protein interaction partners
- 40
- R-HSA-110314
- R-HSA-174411
- R-HSA-174414
- R-HSA-174417
- R-HSA-174437
- R-HSA-5358565
- R-HSA-5358606
- R-HSA-5651801
- R-HSA-5656169
- R-HSA-5685942
- R-HSA-5696397
- R-HSA-5696400
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- End position
- 74669117
- Start position
- 74493851
- Chromosome
- 11
- Strand
- Forward
- Cytoplasm . Nucleus . Note=Partially colocalizes with PCNA and POLD1 at S phase replication sites (PubMed:11595739). Recruited to DNA damage sites within 2 hours following UV irradiation (PubMed:20227374, PubMed:22801543). .
- Nucleoplasm
- PubMed 11595739
- PubMed 20227374
- PubMed 22801543
- Tissue specificity (tau)
- 0.711651
- Expression inequality (Gini)
- 0.332017
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 27.01
- Testis
- 22.44
- Uterus
- 17.18
- Cells - Cultured fibroblasts
- 16.76
- Cervix - Endocervix
- 14.93
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes27.01
- Testis22.44
- Uterus17.18
- Cells - Cultured fibroblasts16.76
- Cervix - Endocervix14.93
- Fallopian Tube14.74
- Cervix - Ectocervix13.43
- Bladder12.08
- Vagina11.62
- Nerve - Tibial11.53
- Ovary11.41
- Lung10.68
- Colon - Sigmoid10.29
- Small Intestine - Terminal Ileum10.04
- Adipose - Subcutaneous9.93
- Prostate9.77
- Spleen9.75
- Breast - Mammary Tissue9.69
- Thyroid9.68
- Esophagus - Gastroesophageal Junction9.66
- Artery - Tibial9.19
- Colon - Transverse9.15
- Esophagus - Muscularis8.71
- Minor Salivary Gland8.55
- Artery - Coronary8.54
And 29 more, listed on the interactive page.
- GO:0006261
- GO:0006297
- GO:0042276
- GO:0071897
- GO:0005634
- GO:0005654
- GO:0016035
- GO:0043625
- GO:0005515
- GO:0030674
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor